Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor of Medicine
David Geffen School of Medicine at UCLA

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Los Angeles, CA

Topics of Professional Interest:
  • Primary HIV infection
  • HIV pathogenesis
  • Antiretroviral therapy
  • HIV-HCV coinfection
  • Management of HIV infection
Current Professional Summary:

Dr Daar is a Professor of Medicine at the David Geffen School of Medicine at UCLA and Chief of the Division of HIV Medicine at Harbor-UCLA Medical Center. Dr Daar's research interests are related to the pathogenesis of acute and chronic HIV-1 infection, the management of HIV-1 infection and its complications, and the interaction between HIV-1 and HCV infection in co-infected individuals.

Committees and Organizations:
  • American Medical Association
  • American Academy for the Advancement of Sciences
  • American Society of Microbiology
  • IAS–USA
  • American Academy of HIV Medicine
  • HIV Medicine Association
  • Antiretroviral Therapy Strategies Subcommittee of AIDS Clinical Trials Group
  • Chair, NIAID HIV Prevention Data and Safety Monitoring Board
Honors and Awards:
  • Alpha Omega Alpha Medical Society, Beta Chapter, Washington, D.C. (1984)
  • Ben Newman Award for Resident Achievement, Cedars-Sinai Medical Center (1988)
  • Morris Press Humanism Award for Attending Staff, Cedars-Sinai Medical Center (1994)
  • Golden Apple Award for Teaching Excellence, Cedars-Sinai Medical Center (1995, 1998)
  • UCLA School of Medicine Award for Excellence in Education (2000)
  • LA Shanti Plus Program Pat Griffin Hero of the Year (2003)
Education:
  • UCLA, BA Biology (1981)
  • Georgetown School of Medicine, MD (1985)
  • Cedars-Sinai Medical Center/UCLA Medical Center, Residency (1985-1988)
  • Cedars-Sinai Medical Center, Fellowship in Infectious Diseases (1988-1991)
Selected Publications:

Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S.  HIV-1 population genetics and adaptation in newly infected individuals.  J Virol. 2009; 83:2715-2727.  [PMID: 19116249].

Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Guenthard H, Richman D, Rice AP, Daar E, Little S, Wong JK.  Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity.  Virology 2009; 387:98-108.  [PMID: 19268337]

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, for the AIDS Clinical Trials Groups Study A5202 Team.   Tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine as part of once-daily regimens for initial treatment of HIV-1 infection.  N Engl J Med 2009; 361:2230-2240.  [PMID: 19952143]

Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R. the California Collaborative Treatment Group.  Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1 infected patients.  AIDS; 2010; 24:707-716.  [PMID: 20087154]

Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul R, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B.  Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era.  J Neurovirol 2010; 16:25-32.  [PMID: 20113183]

Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertora J, Patterson K, Daar ES, Cavert W, Brizz B for the ACTG A5200 team of the ACTG.  Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-infected Subjects.  ACTG 5200.  J Acquir Immune Defic2010; 53(4):491-495[PMID: 20130470]

Rieg G, Butler DM, Smith DM, Daar ES.  Seminal plasma HIV RNA in patients with asymptomatic sexually transmitted infections.  International J STD & AIDS 2010; 21:207-208.  [PMID: 20215629]

Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.  J Virol, 2010; 84:7581-7591.  [PMID: 20504921]

Yang OO, Daar ES, Ng HL, Shih R, Jamieson BD.  Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia.  AIDS Res Human Retroviruses 2011;27:391-398. [PMID: 21087140]

Gorbach PM, Weiss RE, Jeffries R, Javanbakht M, Drumright LN, Daar ES, Little SJ.  Behaviors of recently HIV-infected men who have sex with men in the year post diagnosis:  effects of drug use and partner types.  J Acquir Immune Defic 2010; 56:176-182 [PMID: 21119524]

Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy J-P, Conway B, Kaldor J, Levy J, Schooley R, Cooper D, Altfeld M, Richman D, Connick E.  Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.  J Infect Dis. 2011; 203:442-451 [PMID: 21245157].

Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia BA and the HIV Neuroimaging Consortium.  Persistence of HIV-associated cognitive impairment, inflammation and neuronal injury in the era of highly active antiretroviral treatment.  AIDS. 2011; 25:625-633 [PMID: 21297425].

Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, for the AIDS Clinical Trials Group Study A5202 Team.  Atazanavir plus ritonavir or efavirenz as part of a three drug regimen for initial treatment of HIV-1:  A randomized, controlled equivalence trial.  Ann Intern Med 2011; 154:445-456 [PMID: 21320923].

Tate DF, Sampat M, Harezlak J, Fiecas M, Hogan J, Dewey J, McCaffrey D, Branson D, Russell T, Conley J, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Y, Matesan J, Letendre S, Paulose S, Gaugh M, Tripolica C, Yiannoutsos C, Bigler ED, Cohen RA, Guttmann CR, Navia B, for the HIV Neuroimaging Consortium.  Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.  J Neurovirology 2011; 17:368-379. [PMID: 21556960].

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.  Bone mineral density and fractures in antiretroviral-naïve subjects randomized to abacavir/lamivudine or tenofovir D/emtricitabine along with efavirenz or atazanavir/ritonavir:  AIDS Clinical Trials Group A5224s, a substudy of A5202.  J Infect Dis. 2011; 203:1791-1801 [PMID:  21606537].

McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ESPeripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.Clin Infect Dis 2011; 53:185-196. [PMID: 21690627].

Lagnese M, Daar ES, Christenson P, Rieg G.  Herpes simplex virus type 2 seroprevalence and incidence in acute and chronic HIV-1 infection.  Int J STD & AIDS 2011;  22:463-564. [PMID: 21742810]. 

Wohl AR, Carlos J-A, Tejero J, Dierst-Davies R, Daar ES, Khanlou H, Cadden J, Towner W, Frye D.  Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California.  AIDS Patient Care and STDs 2011; 25:525-532. [PMID 21774689]

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajalah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA, for the AIDS Clinical Trials Groups Study A5202 Team.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV.  J Infect Dis 2011; 204:1191-1201. [PMID 21917892]

Hogan C, DeGruttola V, Sun X, Fiscus S, Del Rio C, Hare B, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Frazier T, Daar ES, Little S, and the A5217 Study Team.  The Setpoint Study (ACTG A5217):  Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.  J Infect Dis 2012; 205:87-96. [PMID 22180621]

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir:  ACTG A5224s, A5202 substudy.  AIDS 2012, 26: 1372-1385 [PMID: 22546988].

Tenckhoff S, Kaiser T, Bredeek F, Donfield S, Menius E, Lail A, Mossner J, Daar ES, Tillmann HS and the Hemophilia Growth and Development Study.  J Acquir Immune Defic2012, Epub ahead of print.  [PMID 23007118].

Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group Protocols implicates several CYP2B6 variants.  Pharmacogenet Gemomics 2012; Epub ahead of print.  [PMID: 23080225].

Poland RE, Gertsik L, Favreau J, Smith SI, Mirocha JM, Rao U, Daar ES.  Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects.  J Altern Complement Med  2012; Epub ahead of print [PMID: 23098696].

Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D, for the AIDS Clinical Trials Group Study A5202 Team.  HIV-1 amino acid changes among participants with virologic failure:  Associations with first-line efavirenz or atazanavir plus ritonavir and disease status.  J Infect Dis 2012.  Epub ahead of print [PMID: 23148287].

Ribaudo HJ, Daar ES, Tierney C, Morse G, Mollan K, Sax P, Fischl MA, Collier AC, Haas DW, and the AIDS Clinical Trials Group.  Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.  J Infect Dis 2012. Epub ahead of print [PMID:  23148286].

Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA.  Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.  Antiviral Therapy 2012, Epub ahead of print [23264445].

McComsey GA, Daar ES, O’Riordan MA, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gershenson M.  Changes in fat mitochondrial DNA and function in subjects randomized to abacavir/lamivudine or tenofovir DF/emtricitabine with atazanavir/ritonavir or efavirenz:  AIDS Clinical Trials Group Study A5224s, substudy of A5202.  J Infect Dis 2013, Epub ahead of print [PMID: 23204164].